Oct. 30, 2022, Baidu Health Internet Hospital (referred as "Baidu Health") and Shanghai Epiprobe Biotechnology Co., Ltd. (referred as "Epiprobe") has announced strategic cooperation to popularize the early pan-cancer screening in clinical and general health channels during the opening ceremony of Epiprobe Biomedical Laboratory held in Heze City, Shandong Province.
Mr. Zhang Kuan, President of Baidu Health Internet Hospital, Ms. Hua Lin, CEO of Epiprobe, and others witnessed the Strategic Cooperation Signing Ceremony. Baidu Health and Epiprobe will utilize each advantage, integrate online and offline services, promote early cancer screening and early diagnosis, and explore integrated health services from cancer prevention popular science to early screening in different fields.
Pursuant to the data, annual medical expenditure of malignant cancers exceeds 220 billion RMB, which has become a vital part of the expenditure of families and medical insurance funds in China. According to Frost & Sullivan, cost of cancer treatment will be increased to USD 351.7 billion in 2023 and USD 592 billion in 2030 in China. Early cancer screening and diagnosis has significantly improved patient’s survival rate, which also has decreased the burden of health care spending on countries and individuals. The Cancer Hospital of the Chinese Academy of Medical Sciences released a paper that early cancer screening can notably prevent cancer and cancer related death. Thus, Baidu Health has cooperated with Epiprobe to implementation of early cancer detection, early diagnosis and early treatment.
Baidu Health, a leading health consultation platform incubated by Baidu, daily serves over 100 million medical and health clients with over 200 million precision medical and health-related searches on average. Over 300,000 doctors in public hospitals provides clients with 2.4 million online medical consultation services through platform on a daily basis.
As the core entrance for users to learn about knowledge of health, 100 million clients daily obtain health knowledge and services through Baidu Health. Currently, Baidu Health has established a health science consultation system through Baidu Health Medical Codex, Baidu Health Baijia and authoritative doctors' Q&A, which has accumulatively recorded 500 million pieces of authoritative health science contents. Health science content covers the whole cycle of prevention, diagnosis, treatment, rehabilitation and health management. Mr. Zhang Kuan, President of Baidu Health Internet Hospital, noted that: "Since establishment, Baidu Health, with the commitment to empowering the health industry through its own big data search and AI technology advantages, proactively cooperates with biomedical enterprises, and creates the platform for advancing new technology products to achieve full-scenario promotion and application. We hope to fully exert the platform's traffic and technical advantages, one-stop health service capabilities, and explore the early pan-cancer screening service model with Epiprobe, so that more clients can realize the value and significance of early screening, jointly build a national early screening service system that combines online and offline, and integrate the prevention and treatment solutions of the oncology expert team of tertiary hospitals, thereby providing whole process and one-stop service of cancer prevention and treatment, upgrading the health industry with digitalization.”
As pioneer of early pan-cancer screening, Epiprobe is a high-tech enterprise that focus on cancer molecular diagnosis and precision medicine industry. Building on the excellent team of epigenetics experts with over 30 years' profound academic research, Epiprobe has explores the field of cancer detection, upheld the vision of "keeping everyone away from cancer," committed to the early detection, early diagnosis and early treatment of cancer, thereby improve the survival rate of cancer patients to enhance the health of the whole population.
Ms. Hua Lin, CEO of Epiprobe noted that: "Early screening to achieve effective screening before cancers occurs, and the current use of pan-cancer markers for early screening has achieved early pan-cancer screening and precancerous monitoring, which can help doctors intervene and eliminate cancer at precancerous stage, thereby notably increasing patient survival rate and reducing the treatment cost." Vision of Epiprobe is to 'Build a Cancer-Free World,' which also expresses our confidence and determination in early cancer screening." Epiprobe has cooperated with Baidu Health to join forces together, and meanwhile lay out the in-hospital and out-of-hospital markets, create an exclusive vertical in-depth service system for clients. Also, Epiprobe provides comprehensive services in clinical applications such as cancer screening, auxiliary diagnosis, prognosis assessment and efficacy recurrence monitoring, thereby achieving the whole process of health services from 'early cancer discovery' to 'cancer prevention in advance.' "
Post time: Oct-30-2022